Table 3.

Bivariate and Multivariate Analysis to Identify Associate Factors of HIV-Associated Neurocognitive Deficit, Ethiopia, 2020 (n=422)

Variables		Neurocognitive Impairment		COR (95% CI)	AOR (95% CI)
		No	Yes
Age (covariate)				1.03 (1.01,1.05)	1.06 (1.03,1.08)*
Sex	Male	111	57	0.61 (0.41,0.92)	0.48 (0.27,0.86)
	Female	138	116	1.00	1.00
Family average monthly income	< 500 ETB	38	43	4.49 (2.53,7.99)	4.22 (2.02,8.81)*
	501–1000	43	67	6.19 (3.62,10.58)	3.93 (2.09,7.36)*
	1001–1500	33	29	3.49 (1.87, 6.52)	1.48 (0.71,3.11)
	≥ 1501	135	34	1.00	1.00
Anxiety	No	244	161	1.00	1.00
	Yes	5	12	3.64 (1.26, 10.52)	1.30 (0.33,5.10)
CD4 count				1.001 (1.00,1.002)	1.001 (1.00,1.002)
Depression	No	226	129	1.00	1.00
	Yes	23	44	3.35 (1.94, 5.80)	0.46 (0.12,1.54)
Depression and anxiety	No	220	104	1.00	1.00
	Yes	29	69	5.03 (3.08,8.24)	5.51 (1.81,16.79)*
Communication about safe sexual intercourse	Yes	212	109	1.00	1.00
	No	37	64	3.36 (2.11,5.36)	2.88 (1.61,5.16)*
Duration of HIV illness in a year				1.006 (1.001,1.01)	1.01 (1.001,1.02)*
Duration of treatment in a year				1.024 (1.003,1.04)	0.92 (0.84,1.01)
Hemoglobin (covariate)				0.82 (0.74,0.91	1.03 (0.89,1.19)
HAART adherence	Yes	230	135	1.00	1.00
	No	19	38	0.63 (0.30, 1.31)	1.20 (0.55,2.62)
Severity of HIV	No symptom	226	140	1.00	1.00
	Had symptom but did not affect ADL	21	23	1.77 (0.94,3.31)	0.63 (0.27,1.50)
	Had symptom and spent half of the day in bed	2	10	8.07 (1.74, 37.38)	1.77 (0.33,9.50)
WHO stage of HIV	Stage I	153	87	1.58 (1.06,2.33)	1.05 (0.61,1.80)
	Stage II and Above	96	86	1.00	1.00
Last month substance use	Yes	21	7	0.46 (0.190, 1.10)	0.55 (0.19,1.57)
	No	228	166	1.00
Social support	Poor support	89	122	5.83 (3.46, 9.82)	3.65 (1.86,7.17)*
	Moderate support	58	27	1.98 (1.05, 3.74)	1.40 (0.67,2.95)
	Strong support	102	24	1.00	1.00

Note: *p-value less than 0.05.